Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women

Clin Pharmacol Ther. 2020 Feb;107(2):315-318. doi: 10.1002/cpt.1605. Epub 2019 Sep 28.
No abstract available

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B / genetics
  • Area Under Curve
  • Atazanavir Sulfate / administration & dosage
  • Atazanavir Sulfate / pharmacokinetics*
  • Chromatography, High Pressure Liquid
  • Citrus sinensis
  • Cytochrome P-450 CYP3A Inhibitors / pharmacology
  • Diarrhea / epidemiology
  • Dose-Response Relationship, Drug
  • Female
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / pharmacokinetics*
  • Hair / chemistry
  • Heroin Dependence / epidemiology
  • Humans
  • Hydrogen-Ion Concentration
  • Longitudinal Studies
  • MicroRNAs
  • Polymorphism, Single Nucleotide
  • Racial Groups
  • Receptors, Cell Surface / genetics*
  • Tandem Mass Spectrometry

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • Cytochrome P-450 CYP3A Inhibitors
  • HIV Protease Inhibitors
  • MicroRNAs
  • Receptors, Cell Surface
  • SORCS2 protein, human
  • Atazanavir Sulfate